It’s West Coast vs East Coast in CRISPR Fight

Subscribe today to listen to this content Get Access

In a significant development for all of life science including orthopedics, the U.S. Court of Appeals for the Federal Circuit has reinstated the University of California, Berkeley’s legal challenge against the Broad Institute’s patents on CRISPR gene-editing technology. This decision revives a high-stakes dispute over the ownership of intellectual property rights for a technology with vast potential for all life science, pharmaceuticals and biotech generally.

At the heart of the case is CRISPR-Cas9—short for Clustered Regularly Interspaced Short Palindromic Repeats—a revolutionary gene-editing tool that acts like molecular scissors. It allows scientists to cut, remove, or replace segments of DNA with extreme precision. Originally identified in bacteria, CRISPR has been repurposed into a programmable system with transformative implications in medicine, agriculture, and biotechnology.